OB3 Stock Overview
OptiBiotix Health Plc, a life sciences company, engages in the discovery and development of microbiome modulators primarily in the United Kingdom.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
OptiBiotix Health Plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£0.28 |
52 Week High | UK£0.30 |
52 Week Low | UK£0.061 |
Beta | 1.56 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | -51.72% |
5 Year Change | n/a |
Change since IPO | -62.26% |
Recent News & Updates
Recent updates
Shareholder Returns
OB3 | DE Biotechs | DE Market | |
---|---|---|---|
7D | 0% | -4.9% | -1.5% |
1Y | n/a | -19.9% | 0.9% |
Return vs Industry: Insufficient data to determine how OB3 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how OB3 performed against the German Market.
Price Volatility
OB3 volatility | |
---|---|
OB3 Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 4.9% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.0% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: OB3 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine OB3's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | 9 | Stephen O'Hara | www.optibiotix.com |
OptiBiotix Health Plc, a life sciences company, engages in the discovery and development of microbiome modulators primarily in the United Kingdom. The company identifies and develops microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that impacts human physiology deriving potential health benefits. Its products include Slimbiome, a natural ingredient, which offers a healthy and hunger-free weight management system; SlimBiome Medical, a natural supplement for weight management; CholBiome, a food supplement for maintaining healthy levels of cholesterol; Lactobacillus plantarum LPLDL, a probiotic that aids elements of cardiovascular and wellbeing; LPGOS, a galactooligosaccharid that is used in food products and applications, which helps in reducing cardiovascular risk factors and enhancing health; and Sweetbiotix, a sweetener for use in food and beverages.
OptiBiotix Health Plc Fundamentals Summary
OB3 fundamental statistics | |
---|---|
Market cap | €27.34m |
Earnings (TTM) | -€15.31m |
Revenue (TTM) | €800.54k |
34.1x
P/S Ratio-1.8x
P/E RatioIs OB3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
OB3 income statement (TTM) | |
---|---|
Revenue | UK£689.00k |
Cost of Revenue | UK£349.00k |
Gross Profit | UK£340.00k |
Other Expenses | UK£13.52m |
Earnings | -UK£13.17m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.14 |
Gross Margin | 49.35% |
Net Profit Margin | -1,912.19% |
Debt/Equity Ratio | 0% |
How did OB3 perform over the long term?
See historical performance and comparison